Standout Papers

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with S... 1994 2026 2004 2015 2.2k
  1. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer (1996)
    William P. McGuire, William J. Hoskins et al. New England Journal of Medicine
  2. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer (2011)
    Robert A. Burger, Mark F. Brady et al. New England Journal of Medicine
  3. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma (1994)
    Mark F. Brady, Harrison Ball et al. American Journal of Obstetrics and Gynecology
  4. Inherited Mutations in Women With Ovarian Carcinoma (2015)
    Barbara M. Norquist, Maria I. Harrell et al. JAMA Oncology
  5. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup (2009)
    Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology
  6. Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study (1993)
    Francis J. Major, John A. Blessing et al. Cancer
  7. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial (2017)
    Robert L. Coleman, Mark F. Brady et al. The Lancet Oncology
  8. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer (2016)
    John K. Chan, Mark F. Brady et al. New England Journal of Medicine

Immediate Impact

4 by Nobel laureates 1 from Science/Nature 109 standout
Sub-graph 1 of 14

Citing Papers

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
2020 Standout
5 intermediate papers

Works of Mark F. Brady being referenced

Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study
2001
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
1996
and 3 more

Author Peers

Author Last Decade Papers Cites
Mark F. Brady 8175 3609 3801 3613 108 11.7k
Robert S. Mannel 7593 2968 5929 3425 202 13.1k
Robert A. Burger 8870 4310 3648 4510 200 14.4k
Howard D. Homesley 6302 2881 5676 2477 173 11.0k
Karl C. Podratz 7049 3372 7022 2930 263 13.5k
John A. Blessing 5982 3834 7536 2865 259 12.6k
Helen Huang 4678 2616 2492 2821 66 7.9k
Vincent T.H.B.M. Smit 3376 1501 4395 3655 192 11.6k
Martee L. Hensley 3672 1572 3754 4081 220 12.9k
C. Blake Gilks 4471 1401 3177 4889 177 13.9k
Brian N. Bundy 9790 8946 12686 4297 110 21.8k

All Works

Loading papers...

Rankless by CCL
2026